Hemispherx: FDA decision on Ampligen won't come until fall

07/23/2009 | American City Business Journals

The FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because of staffing problems, said Dr. William Carter, the company's president and CEO. The biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners while the agency reviews the product.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA